Immune correlates to an inactivated H5N1 vaccine in humans

人类免疫与灭活 H5N1 疫苗相关

• 批准号: G0700647/1
• 负责人: Xiao-Ning Xu
• 金额: $ 12.67万
• 依托单位: Medical Research Council
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2007
• 资助国家: 英国
• 起止时间: 2007 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0700647%2F1
• 关键词: Immune; correlates; inactivated; H5N1; vaccine

An effective vaccine would be the first choice for protection against future pandemic influenza infection. Hundreds of millions of vaccine doses would be required to prevent the first wave of the disease in a pandemic. However, because influenza virus can mutate quickly, one cannot predict exactly which strain of influenza virus will be next the pandemic virus. Therefore, a vaccine would not only have to be effective but would also have to be made in a very short period of time. The current avian flu vaccine (H5N1) is poorly immunogenic in humans and has to be used at a 10-fold higher doses than the seasonal influenza vaccines and more than one shot is needed to reach protective levels of antibody. The amount of the vaccine required is therefore far beyond the present worldwide manufacturing capacity and current candidate vaccines may be too slow in stimulating protection. The simplest way to solve this problem would be to lower the dose and number of shots required for protection by increasing the immunogenicity of the vaccine. This research project aims to study how to enhance the immune responses to avian influenza vaccines in a Phase II clinical trial. The outcome of this study will help to develop an effective vaccine requiring a lower dose to protect against H5N1 infection.

有效的疫苗将是预防未来大流行性流感感染的首选。要预防大流行中的第一波疾病，需要数亿剂疫苗。然而，由于流感病毒可以迅速变异，人们无法准确预测哪种流感病毒株将成为下一个大流行病毒。因此，疫苗不仅必须有效，而且必须在很短的时间内制成。目前的禽流感疫苗（H5N1）对人类的免疫原性很差，必须以比季节性流感疫苗高10倍的剂量使用，并且需要多次注射才能达到保护抗体水平。因此，所需疫苗的数量远远超出目前世界范围的生产能力，目前的候选疫苗在刺激保护方面可能过于缓慢。解决这个问题最简单的方法是通过增加疫苗的免疫原性来降低保护所需的剂量和注射次数。本研究项目旨在研究如何在第二阶段临床试验中增强对禽流感疫苗的免疫应答。这项研究的结果将有助于开发一种有效的疫苗，需要较低的剂量，以防止H5N1感染。